Efficacy of MK615 for the treatment of patients with liver disorders

Figure 1 Experiment protocol of D-galactosamine hydrochloride-induced acute hepatic injury in rats.

Figure 2 Effect of MK615 in D-galactosamine hydrochloride-induced acute hepatic injury in rats. A: AST plasma levels; B: ALT plasma levels; C: Control group (liver); D: MK615 group (liver). AST:Aspartate aminotransferase; ALT: Alanine aminotransferase.

Figure 3 Effects of MK615 in patients with liver disorder, chronic hepatitis C and non-alcoholic fatty liver disease. A: Alanine aminotransferase (ALT); B: Aspartate aminotransferase (AST); C: Chronic hepatitis C group (ALT); D: Non-alcoholic fatty liver disease group (ALT). ^aP < 0.05 vs 0 wk group. Dunnett’s test.

Figure 4 Effects of MK615 in patients with chronic hepatitis C (alanine aminotransferase). A: Misatol was added on ursodeoxycholic acid; B: Only Misatol was used. ^aP < 0.05 vs 0 wk group. Dunnett’s test. NS: Not significant.